Introduction: Progressive supranuclear palsy is a neurodegenerative disorder, described as a tauopathy. The neuroimaging and visual symptoms are among the most important in the diagnosis of this disease. The ophthalmoparesis mainly concerns voluntary eye movements. Patients mostly present with vertical palsy, involuntary eye movements, convergence insufficiency, and diplopia.
Case report: A 62-year-old female patient was admitted to the hospital because of the gait disturbance and frequent falls. She had impaired memory, handwriting and speech for one year. On neurological and neuro-ophthalmological examinations, the patient presented with vertical gaze palsy, involuntary eye movements, dysarthria, tremor in the right hand, and cerebellar ataxia. Blood tests were normal. (18F)-FDG PET revealed bilateral zones of moderate hipometabolism in the regions of posterior frontal cortex, anterior cingulum, left thalamus, head of left striatum, and left temporal lobe. Neuropsychological tests revealed cognitive impairment (MMSE-26; IADL-1).
Conclusion: Based on the literature review and our own notices, we suggest that (18F)-FDG PET scanning and neuro-ophthalmological examination in addition to structural neuroimaging and clinical findings play a crucial role in the differential diagnosis of PSP and other parkinsonian syndromes.
Akdemir Ü, A Tokçaer, A Karakuş, L Kapucu. Brain 18F-FDG PET imaging in the differential diagnosis of Parkinsonism. Clinical Nuclear Medicine, 2014;39(3):225-314.
Amtage F, C Maurer, S Hellwig, et al. Functional correlates of vertical gaze palsy and other ocular motor deficits in PSP: An FDG-PET study. Parkinsonism & Related Disorders, 2014;20(8):898-906.
Berti V, A Pupi, L Mosconi. PET/CT in diagnosis of movement disorders. Annals of the New York Academy of Sciences, 2011;1228:93-108.
Borroni B, A Benussi, A Pilotto, et al. Diagnosing progressive supranuclear palsy: role of biological and neuroimaging markers. J Alzheimers Dis Parkinsonism, 2014;4:6.
Botha H, J Whitwell, A Madhaven, M Senjem, V Lowe, K Josephs. The pimple sign of progressive supranuclear palsy syndrome. Parkinsonism & Related Disorders, 2014;20(2):180-185.
Gerhard A. Imaging of neuroinflammation in Parkinsonian syndromes with positron emission tomography. Curr Neurol Neurosci Rep, 2013;13:405.
Hellwig S, M Reinhard, F Amtage, et al. Transcranial sonography and [18F]fluorodeoxyglucose positron emission tomography for the differential diagnosis of parkinsonism: a head-to-head comparison. Eur J Neurol, 2014;21(6):860-866.
Jin S, M Oh, S Oh, et al. Differential diagnosis of Parkinsonism using dual-phase F-18 FP-CIT PET imaging. Nucl Med Mol Imag, 2013;47(1):44-51.
Srulijes K, M Reimold, R Liscic, et al. Fluorodeoxyglucose positron emission tomography in Richardson`s syndrome and progressive supranuclear palsy-parkinsonism. Movement Disorders, 2012;27(1):151-155.
Takahashi R, K Ishii, T Kakigi, T Yokoyama, E Mori, T Murakami. Brain alterations and Mini-Mental State Examination in patients with progressive supranuclear palsy: Voxel-Based investigations using 18F-Fluorodeoxyglucose positron emission tomography and magnetic resonance imaging. Dement Geriatr Cogn Dis Extra, 2011;1(1):381-392.
Teune L, A Bartels, B Jong, et al. Typical cerebral metabolic patterns in neurodegenerative brain diseases. Movement Disorders, 2010;25(14):2395-2404.
Teune L, R Renken, D Mudali, et al. Validation of parkinsonian disease-related metabolic brain patterns. Movement Disorders, 2013;28(4):547-551.
Tripathi M, V Dhawan, S Peng, et al. Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography. Neuroradiology, 2013;55(4):483-492.
Zalewski N, H Botha, J Whitwell, V Lowe, D Dickson, K Josephs. FDG-PET in pathologically confirmed spontaneous 4R-tauopathy variants. J Neurol, 2014;261(4):710-716.
Zhao P, B Zhang, S Gao. 18[F]-FDG PET study onthe idiopathic Parkinson`s disease from several parkinsonian-plus syndromes. Parkinsonism & Related Disorders, 2012;18(Suppl. 1):S60-S62.
Email this article (Login required) 
